# Curis Inc: overview CRIS · Nasdaq · CIK 1108205 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/cris.md) · [Financials](/companies/cris/financials.md) · [Filings](/companies/cris/filings.md) · [Insiders](/companies/cris/insiders.md) Latest reported revenue: [$0](/filings/0001108205-26-000118.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 14, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001108205-26-000118). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $k | [2,931](/filings/0001108205-25-000107.md) | [3,345 d](/filings/0001108205-26-000043.md) | [2,380](/filings/0001108205-26-000061.md) | [2,749](/filings/0001108205-26-000118.md) | [3,176](/filings/0001108205-25-000107.md) | [1,138 d](/filings/0001108205-26-000043.md) | [0.0](/filings/0001108205-26-000061.md) | [0.0](/filings/0001108205-26-000118.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(360.5%)](/filings/0001108205-25-000107.md) | [(268.9%) d](/filings/0001108205-26-000043.md) | [(426.8%)](/filings/0001108205-26-000061.md) | [(300.1%)](/filings/0001108205-26-000118.md) | [(218.0%)](/filings/0001108205-25-000107.md) | [1724.0% d](/filings/0001108205-26-000043.md) | not reported | not reported | | Net margin | % | [(344.3%)](/filings/0001108205-25-000107.md) | [(287.5%) d](/filings/0001108205-26-000043.md) | [(446.1%)](/filings/0001108205-26-000118.md) | [(312.6%)](/filings/0001108205-26-000118.md) | [(243.4%)](/filings/0001108205-25-000107.md) | [1700.9% d](/filings/0001108205-26-000043.md) | not reported | not reported | | Diluted EPS | $ per share | [(1.70)](/filings/0001108205-25-000107.md) | not reported | [(1.25)](/filings/0001108205-26-000061.md) | [(13.61)](/filings/0001108205-26-000118.md) | [(0.49)](/filings/0001108205-25-000107.md) | not reported | [(1.25)](/filings/0001108205-26-000061.md) | [(4.02)](/filings/0001108205-26-000118.md) | | Free cash flow | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [10.6](/filings/0001108205-23-000023.md) | [10.2](/filings/0001108205-24-000010.md) | [10.0](/filings/0001108205-25-000031.md) | [10.9](/filings/0001108205-26-000043.md) | [9.4](/filings/0001108205-26-000043.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(395.0%)](/filings/0001108205-23-000023.md) | [(521.7%)](/filings/0001108205-24-000010.md) | [(482.2%)](/filings/0001108205-25-000031.md) | [(408.3%)](/filings/0001108205-26-000043.md) | [(60.5%)](/filings/0001108205-26-000043.md) | | Net margin | % | [(426.7%)](/filings/0001108205-23-000023.md) | [(557.7%)](/filings/0001108205-24-000010.md) | [(473.0%)](/filings/0001108205-25-000031.md) | [(397.8%)](/filings/0001108205-26-000043.md) | [(80.3%)](/filings/0001108205-26-000043.md) | | Diluted EPS | $ per share | [0.50](/filings/0001108205-23-000023.md) | [(12.14)](/filings/0001108205-24-000010.md) | [(8.96)](/filings/0001108205-25-000031.md) | [(6.88)](/filings/0001108205-26-000043.md) | [(0.58)](/filings/0001108205-26-000043.md) | | Free cash flow | $m | [(37.6)](/filings/0001108205-23-000023.md) | [(54.8)](/filings/0001108205-24-000010.md) | [(38.4)](/filings/0001108205-25-000031.md) | not reported | not reported | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/cris/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [SBI Securities Co., Ltd.](/funds/1851815.md) | 2026-06-30 | $8 | 15 | | New +15 | ## Recent filings [All 823 filings](/companies/cris/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-19 | 20:30 ET | [8-K](/filings/0001104659-26-116910.md) | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 9.01 Financial statements and exhibits | 0001104659-26-116910 | | 2026-08-14 | 20:02 ET | [10-Q](/filings/0001108205-26-000118.md) | Quarterly report, period 2026-06-30 | 0001108205-26-000118 | | 2026-08-10 | 21:30 ET | [S-1](/filings/0001108205-26-000109.md) | Registration statement | 0001108205-26-000109 | | 2026-07-30 | 20:01 ET | [8-K](/filings/0001108205-26-000105.md) | 3.01 Delisting notice | 0001108205-26-000105 | | 2026-07-02 | 12:56 ET | [8-K](/filings/0001108205-26-000078.md) | 3.03 Change to security holders’ rights; 5.03 Amendment to articles or bylaws; 9.01 Financial statements and exhibits | 0001108205-26-000078 | | 2026-07-01 | 15:22 ET | [8-K/A](/filings/0001108205-26-000076.md) | 5.03 Amendment to articles or bylaws | 0001108205-26-000076 | | 2026-07-01 | 12:02 ET | [8-K](/filings/0001108205-26-000074.md) | 5.03 Amendment to articles or bylaws | 0001108205-26-000074 | | 2026-06-25 | 20:01 ET | [8-K](/filings/0001108205-26-000071.md) | 5.07 Shareholder vote results | 0001108205-26-000071 | | 2026-06-05 | 13:06 ET | [DEF 14A](/filings/0001108205-26-000068.md) | Proxy statement, period 2026-06-25 | 0001108205-26-000068 | | 2026-05-22 | 20:02 ET | [8-K](/filings/0001108205-26-000065.md) | 3.03 Change to security holders’ rights; 5.03 Amendment to articles or bylaws; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001108205-26-000065 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001108205-26-000043.md), filed Mar 24, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/d82804b4-9391-4379-992f-5952f862d3e7) ## About the filer - CIK: 1108205 - Tickers: CRIS - Exchange: Nasdaq - SIC code: 2836 Biological Products, (No Diagnostic Substances) - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:33 ET. No prices; not investment advice.